使用药理动力学和药理动力学分析来优化Fanastomig (EMB-02) 在患有高级固体瘤的患者的剂量方案
Chengjun Jiang1, Fang Ren1, Mingfei Zhang1
1Hanghai EpimAb Biotherapeutics Co., Ltd, Shanghai EpimAb Biotherapeutics, Shanghai, China.
CPT: pharmacometrics & systems pharmacology
|March 11, 2025
概括
范阿斯托米格 (Fanastomig) 是一种用于高级固体瘤的新型双特异性抗体,在I期试验中表现出良好的耐受性和安全性. 使用人口药理动力学和暴露-反应建模,确定了推的II期剂量.
科学领域:
- 免疫治疗是一种免疫疗法.
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 范阿斯托米格 (EMB-02) 是一种针对PD-1和LAG-3的双特异性抗体,用于高级固体瘤.
- 一项首次在人身上进行的第一阶段研究评估了其安全性,PK,PD,免疫性和疗效.
研究的目的:
- 确定Fanastomig.推的第二阶段剂量 (RP2D).
- 进行群体药理动力学 (PopPK) 和暴露-反应 (E-R) 分析.
- 评估Fanastomig在高级固体瘤中的安全性,耐受性和临床疗效.
主要方法:
- 种群药动力学 (PopPK) 建模以评估药物暴露和共变量关系.
- 非线性Emax建模以确定PD-1受体占用率 (RO) 和EC50.
- 建模和模拟以确定最佳的剂量方案 (例如,每周剂量).
- 对抗药物抗体 (ADA) 发生率和对PK/疗效的影响的分析.
主要成果:
- 波普克模型显示,对Fanastomig暴露 (AUC,Cmax) 没有显著的共同变量影响.
- 估计PD-1RO的EC50为0.084微克/毫升;90%瘤RO的目标低谷度为~2.27微克/毫升.
- 预计每周服用360毫克的剂量可以在90%的患者中达到全周围血液RO.
- 高ADA发病率 (95.7%) 对PK/疗效的影响很小;过敏反应在PK暴露时呈反向趋势.
- 范阿斯托米格 (Fanastomig) 耐受性高达900毫克QW,可接受的安全性.
结论:
- 根据安全性,PK和PD数据,选择了两个剂量方案进行进一步的临床开发.
- 范阿斯托米格 (Fanastomig) 显示出作为一种耐受性良好的免疫疗法,可用于高级固体瘤.
- 该研究成功地为在第二阶段试验中进一步调查Fanastomig奠定了基础.
相关概念视频
Biopharmaceutics and Pharmacokinetics: Overview
1.8K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
1.8K
Analysis of Population Pharmacokinetic Data
211
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
211
Drug Dosage Regimen: Overview
3.4K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.4K
Model Approaches for Pharmacokinetic Data: Compartment Models
69
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
Two primary types of compartment models are recognized: mammillary and catenary. The more...
69
Pharmacokinetic Models: Overview
539
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
539
Nonlinear Pharmacokinetics: Overview
245
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
245


